

Stock Idea @ Dalal & Broacha

BUY	
Current Price	479
52 Week Range	254/519
Target Price	575
Upside	20

Key Share Data	
Market Cap (Rs.bn)	64
Market Cap (US\$ mn)	865
No of o/s shares (mn)	133
Face Value	2
BSE Code	511196
NSE Code	CANFINHOME
Bloomberg	CANF:IN



% Shareholding	Sep-20	Jun-20
Promoters	30.0	30.0
DIIs	12.74	11.12
Others	56.80	57.78
Total	100.0	100.0

Can Fin Homes has reported strong profitability over the years (5yrs Avg ROE of 20% and ROA of 1.9%), supported by a stable margin, better operating efficiency and lower credit cost. During Q2FY21, loan growth moderated to 6% YoY, though fresh disbursals picked up to Rs 825 cr vs Rs 401 cr QoQ. Collection efficiency stands at $^\circ$ 93% (excluding prepayments/foreclosures). Costs control was maintained with C-I at 11.9% vs 15.4/11.2% YoY/QoQ. Total covid provisions on the balance sheet currently stand at Rs 86 Cr (0.41% of loan book), which the management believes are adequate to absorb the expected slippages over the next 2-3 quarters.

We believe a high proportion of salaried and low builder loan exposure (0.03% of book) will support asset quality with lower loan losses. In the near-term, the company's focus will remain on collections rather than growth. AUM growth for FY21 is expected to be ~8-10% in FY21 with normalcy returning by H1FY22. We continue to believe that Can Fin is one of the better positioned players in the housing finance sector with a strong balance sheet, granular loan book (Avg ticket size Rs 18 lakh) and sound underwriting standards.

Best in class asset quality among all major peers; CFH's GNPA ratio in Q2FY21 stood at 0.78% (Excluding standstill), as compared to 1.8-4% range for the other major HFC players. Company's robust asset quality has been supported by its prudent underwriting standards, strong recovery practices, better appraisal norms & stringent risk monitoring mechanisms. Increasing focus on lower-risk salaried clientele (71% of loan book) and avoidance of higher-risk large-ticket nonhousing businesses (11% of loan book) also helps maintain superior asset quality. While the company's asset quality will come under pressure in the coming quarters, its actual loan loss will be lower due to higher proportion of salaried customers, with a reasonable presence in non-metro. Besides, the company has a seasoned book and does not have any major exposure to builder loans, and is thus not exposed to risky developer financing.

Improving demand traction in affordable housing: Of late, the real estate sector has seen some green shoots of demand revival with some state governments cutting stamp duty charges and developers offering discounts and freebies during the festive season. The improvement in demand has been also due to pent-up demand in the wake of the nationwide lockdown in India from late March to June. The other reason for the demand spike has been increasing affordability due to lower interest rates. Increasing urbanization, continued fiscal incentives and low penetration of mortgages are key reasons on which we believe demand for housing finance will continue to grow.

Valuation & Outlook

We remain positive on the stock given its favorable loan mix, sustained margins, comfortable liquidity position and robust CAR (25%). Pick up in fresh disbursals QoQ is also comforting. Once the coronavirus scare comes down, with interest rates going down, there is a good chance that demand will start reviving from Q4FY21 onwards since we believe that deferred demand would come back. While NPA recognition will kick in from upcoming quarter, we believe that Can Fin Homes would be in a relatively better position from an asset quality standpoint, given its historical track record and other qualitative aspects, including stringent loan underwriting criteria and negligible developer exposure.

At CMP, the stock trades at 2.7x its FY21E Adj BV & 2.2x its FY22E Adj Bv, which lower than its 5-yrs historical avg of 2.8 times & peak valuation of 5.7 times book value. Thus, we recommend investors to buy this stock, with a price target of Rs 575, valuing the stock at 2.7x FY22E Adj BV.

Financials (Rs. Mn)						
Years	NII	PPOP	PAT	EPS	Adj. BVPS	P/ABV	RoA
FY20	6549	5786	3744	28	153	3.1	1.9
FY21	7327	6415	4089	31	175	2.7	1.9
FY22	8314	7287	5081	38	213	2.2	2.0



Stock Idea @ Dalal & Broacha

P&L (Rs Mn)	FY19	FY20	FY21	FY22
Interest income	16996	19991	21635	24295
Interest expense	11693	13442	14308	15981
NII	5303	6549	7327	8314
Non-interest income	318	314	260	332
Net revenues	5621	6862	7587	8646
Operating expenses	915	1,076	1,171	1,359
PPOP	4706	5786	6415	7287
Provisions	11	603	949	494
PBT	4695	5183	5466	6793
Tax	1,728	1,439	1,378	1,712
PAT	2967	3744	4089	5081

Balance sheet	FY19	FY20	FY21	FY22
Share capital	266	266	266.308	266.308
Reserves & surplus	17556	21234	24963	29623
Net worth	17822	21501	25229	29889
Borrowings	166448	185063	204154	240381
Other liability	3025	3872	1492	1535
Total liabilities	187295	210436	230875	271805
Fixed assets	99	379	398	418
Investments	163	243	265	291
Loans	182342	205257	224083	264783
Cash	4203	3924	5419	5537
Other assets	489	633	707	773
Total assets	187295	210436	230875	271805

Ratios	FY19	FY20	FY21	FY22	
Growth (%)					
NII	4	23	12	13	
PPOP	4	23	11	14	
PAT	4	26	9	24	
Advances	17	13	9	18	
	Spread ((%)			
Yield on Funds	10.0	10.3	10.1	9.9	
Cost of Funds	7.7	7.6	7.4	7.2	
Spread	2.4	2.7	2.7	2.7	
NIM	3.1	3.3	3.3	3.3	
А	sset quali	ty (%)			
Gross NPAs	0.6	0.8	1.4	1.1	
Net NPAs	0.4	0.5	0.8	0.6	
Provisions	30	29	40	46	
R	eturn rati	os (%)			
RoE	18.2	19.0	17.5	18.4	
RoA	1.7	1.9	1.9	2.0	
	Per share	(Rs)			
EPS	22	28	31	38	
BV	134	161	189	224	
ABV	128	153	175	213	
Valuation (x)					
P/E	21.5	17.0	15.6	12.6	
P/BV	3.6	3.0	2.5	2.1	
P/ABV	3.7	3.1	2.7	2.2	



Stock Idea @ Dalal & Broacha

Disclaimer

Dalal & Broacha Stock Broking Pvt Ltd, hereinafter referred to as D& B (CIN_U67120MH1997PTC111186) was established in 1997 and is an integrated financial services player offering an extensive range of financial solutions and services to a wide spectrum of customers with varied needs ranging from equities to mutual funds to depository services.

D&B is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). D&B along with its affiliates offers the most comprehensive avenues for investments and is engaged in the securities businesses including stock broking (Institutional and retail), depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.dalal-broacha.com

D&B is registered as Research Analyst with SEBI bearing registration Number INH000001246 as per SEBI (Research Analysts) Regulations, 2014.

D&B hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in any time in the past. It has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on D&B for certain operational deviations in routine course of business.

D&B offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by D&B (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

D&B or its associates may have financial interest in the subject company.

D&B or its associates do not have any material conflict of interest in the subject company.

The Research Analyst or Research Entity (D&B) has not been engaged in market making activity for the subject company.

D&B or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Disclosures in respect of Research Analyst:

Whether Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities	No
of the subject company at the end of the month immediately preceding the date of publication of	
Research Report:	
Whether the Research Analyst or his/her relative's financial interest in the subject company.	No
Whether the research Analyst has served as officer, director or employee of the subject company	No
Whether the Research Analyst has received any compensation from the subject company in the past	No
twelve months	
Whether the Research Analyst has managed or co-managed public offering of securities for the subject	No
company in the past twelve months	
Whether the Research Analyst has received any compensation for investment banking or merchant	No
banking or brokerage services from the subject company in the past twelve months	



Stock Idea @ Dalal & Broacha

Whether the Research Analyst has received any compensation or other benefits from the subject No	Whether the Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
company or third party in connection with the research report	, , ,	No

D&B and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject D&B or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to D&B. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of D&B . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of D&B or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Contact	Email ID	Contact No.	Sector
Mr. Kunal Bhatia	kunal.bhatia@dalal-broacha.com	022 67141442	Auto, Auto Ancillary, FMCG
Mrs.Charulata Gaidhani	charulata.gaidhani@dalal-broacha.com	022 67141446	Pharma /Healthcare
Mr. Mayank Babla	mayank.babladalal-broacha.com	022 67141412	I.T/Telecom/Media
Mr. Avinash Tanawade	avinash.tanawade@dalal-broacha.com	022 67141449	BFSI
Mr. Akshay Ashok	akshay.ashok@dalal-broacha.com	022 67141486	BFSI
Mr. Suraj Nandu	suraj.nandu@dalal-broacha.com	022 67141438	Associate

Address: - 508, Maker Chambers V, 221 Nariman Point, Mumbai 400 021 Tel: 91-22- 2282 2992, 2287 6173, Fax: 91-22-2287 0092 E-mail: research@dalalbroachaindia.com